PMID- 12051403
OWN - NLM
STAT- MEDLINE
DCOM- 20030122
LR  - 20191210
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 20
IP  - 2
DP  - 2002 Mar-Apr
TI  - The association of serum matrix metalloproteinases and their tissue inhibitor 
      levels with scleroderma disease severity.
PG  - 221-4
AB  - OBJECTIVE: Matrix metalloproteinase 3 (MMP-3) is reported to play an important 
      role in the pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid 
      arthritis (RA). Studies have also investigated the association of different 
      tissue inhibitors of MMPs (TIMPs) with fibrosis in scleroderma (SSc). The aim of 
      this study was to evaluate the correlation of serum MMP-1, 3 and TIMP-1 with 
      severity and disease specific markers of SSc and RA. METHODS: Serum MMP-1,3 and 
      TIMP-1 were measured in 42 SSc patients (age range 28-68 yr mean 47 yr) and 
      compared to 29 RA and 30 healthy age- and sex-matched individuals. Elevated 
      values of MMPs and TIMP-1 were defined as those greater than 2 SD above the 
      normal mean. All SSc and RA patients were scored for disease severity. RESULTS: 
      Serum MMP-1 was significantly elevated in 8/42 (19%) SSc patients (p = 0.01) but 
      only in 2/29 (7%) RA patients (p = 0.2). Whereas MMP-3 levels were elevated in 
      10/29 (34%) RA patients (p = 0.002), it was elevated in only 5/42 (12%) SSc 
      patients (p = 0.03). TIMP-1 was found elevated in 17/42 (40%) SSc patients (p = 
      0.001) and in only 4/29 RA patients (with a strong trend towards significance, p 
      = 0.052). We found a significant association between the elevation of both MMPs 
      and TIMP-1 levels, with the severity of SSc. Those who had an increase of more 
      than one MMP and/or TIMP, demonstrated life-threatening major organ involvement 
      such as end stage lung fibrosis, GI aperislasis, and severe cardiacfailure. 
      Contrary to that in SSc, the severity of RA showed some trend of association with 
      MMP-3 only. CONCLUSION: We confirm previous observations that MMPs and TIMPs may 
      play an important role in various rheumatic diseases. Whereas serum increase of 
      MMP-3 correlated with RA severity, SSc severity was more characterized by the 
      increase of both MMP-1 and TIMP-1. This suggests that the MMPs and TIMPs involved 
      in SSc are different than those playing a role in RA, which may indicate that in 
      SSc they are produced in different locations than in RA.
FAU - Toubi, E
AU  - Toubi E
AD  - Division of Clinical Immunology, Bnai Zion Medical Center, Faculty of Medicine, 
      Technion-Haifa, Israel.
FAU - Kessel, A
AU  - Kessel A
FAU - Grushko, G
AU  - Grushko G
FAU - Sabo, E
AU  - Sabo E
FAU - Rozenbaum, M
AU  - Rozenbaum M
FAU - Rosner, I
AU  - Rosner I
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Biomarkers)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/*blood
MH  - Biomarkers/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 1/*blood
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Scleroderma, Systemic/*blood/classification
MH  - Severity of Illness Index
MH  - Tissue Inhibitor of Metalloproteinase-1/*blood
EDAT- 2002/06/08 10:00
MHDA- 2003/01/23 04:00
CRDT- 2002/06/08 10:00
PHST- 2002/06/08 10:00 [pubmed]
PHST- 2003/01/23 04:00 [medline]
PHST- 2002/06/08 10:00 [entrez]
PST - ppublish
SO  - Clin Exp Rheumatol. 2002 Mar-Apr;20(2):221-4.